Drugs / OVV-01
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05271279 | Dec 2021 → Aug 2022 | lymphoma | Beijing Boren Hospital | Terminated | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07650825 | Aug 2026 → Jan 2027 expected | cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04787003 | Feb 2021 → Oct 2023 | neoplasm | North China Petroleum Bureau General Hospital | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07650838 | Aug 2026 → Dec 2027 expected | soft tissue sarcoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07648472 Comparator | Apr 2026 → Apr 2027 expected | cancer | Joint Biosciences Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OVV-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04787003 ↗ |
| Route | Other | “OVV-01 was intratumorally injected biweekly” PMID 40480657 ↗ Jun 2025 |